Serious fungal infections in Peru

Original Article
Part of the following topical collections:
  1. Global Fungal Disease Burden

Abstract

Epidemiological data about mycotic diseases are limited in Peru and estimation of the fungal burden has not been previously attempted. Data were obtained from the Peruvian National Institute of Statistics and Informatics, UNAIDS and from the Ministry of Health’s publications. We also searched the bibliography for Peruvian data on mycotic diseases, asthma, COPD, cancer and transplants. Incidence or prevalence for each fungal disease were estimated in specific populations at risk. The Peruvian population for 2015 was 31,151,543. In 2014, the estimated number of HIV/AIDS and pulmonary tuberculosis cases was 88,625, 38,581 of them not on ART, and 22,027, respectively. A total of 581,174 cases of fungal diseases were estimated, representing approximately 1.9% of the Peruvian population. This figure includes 498,606, 17,361 and 4,431 vulvovaginal, oral and esophageal candidiasis, respectively, 1,557 candidemia cases, 3,593 CPA, 1,621 invasive aspergillosis, 22,453 allergic bronchopulmonary aspergilllosis, 29,638 severe asthma with fungal sensitization, and 1,447 Pneumocystis pneumonia. This first attempt to assess the fungal burden in Peru needs to be refined. We believe the figure obtained is an underestimation, because of under diagnosis, non-mandatory reporting and lack of a surveillance system and of good data about the size of populations at risk.

Notes

Compliance with ethical standards

Potential conflicts of interest

Dr. Beatriz Bustamante currently receives funding for research from Merck Sharp & Dohme Corp (Merck Investigators Studies Program).

Dr. David W. Denning holds Founder shares in F2G Ltd a University of Manchester spin-out antifungal discovery company, in Novocyt which markets the Myconostica real-time molecular assays and has current grant support from the National Institute of Health Research, Medical Research Council, Global Action Fund for Fungal Infections and the Fungal Infection Trust. He acts or has recently acted as a consultant to Astellas, Sigma Tau, Basilea, Scynexis, Cidara and Pulmocide. In the last 3 years, he has been paid for talks on behalf of Astellas, Dynamiker, Gilead, Merck and Pfizer. He is also a member of the Infectious Disease Society of America Aspergillosis Guidelines and European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines groups.

Dr. Pablo E. Campos currently receives funding to conduct clinical trials from Bristol-Myers Squibb Peru and from Merck Sharp & Dohme Peru.

References

  1. 1.
    Instituto Nacional de Estadística e Informática-Perú (2001) Estimaciones y Proyecciones de Población, 1950–2015, Boletín de Análisis Demográfico No 36. In: http://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib0466/Libro.pdf. Accessed 30 January 2017
  2. 2.
    Ministerio de Salud del Peru (2013) Informe nacional sobre los progresos realizados en el país Perú. Periodo 2012-diciembre 2013Google Scholar
  3. 3.
    Direccion General de Epidemiologia (2014) Peru AIDS cases according to the year of diagnosis, 1983–2014. In: Situación del VIH/SIDA en el Perú. Boletín Epidemiológico Mensual-Diciembre 2014, Red Nacional de Epidemiologia (RENACE)-DGE-MINSA. In: http://www.dge.gob.pe/portal/docs/vigilancia/vih/Boletin_2014/diciembre.pdf. Accessed 30 January 2017
  4. 4.
    Informe Operacional Año (2014) Estrategia Sanitaria Nacional de Prevención y Control de Tuberculosis, MINSA, LimaGoogle Scholar
  5. 5.
    Sobel J (2007) Vulvovaginal candidosis. Lancet 369(9577):1961–1971CrossRefPubMedGoogle Scholar
  6. 6.
    Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J (2013) Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 17(3):340–345CrossRefPubMedGoogle Scholar
  7. 7.
    Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, González-Ramírez I, Ponce-de-León S (2003) The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients: a 12-year study in a referral center in Mexico. Medicine 82(1):39–50CrossRefPubMedGoogle Scholar
  8. 8.
    Matee MI, Scheutz F, Moshy J (2000) Occurrence of oral lesions in relation to clinical and immunological status among HIV-infected adult Tanzanians. Oral Dis 6:106–111CrossRefPubMedGoogle Scholar
  9. 9.
    Smith E, Orholm M (1990) Trends and patterns of opportunistic diseases in Danish AIDS patients 1980–1990. Scand J Infect Dis 22(6):665–672CrossRefPubMedGoogle Scholar
  10. 10.
    Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT, Investigators HOPS (2010) AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS 24(10):1549–1559CrossRefPubMedGoogle Scholar
  11. 11.
    Arendrup MC (2010) Epidemiology of invasive candidiasis. Curr Opin Crit Care 16:445–452CrossRefPubMedGoogle Scholar
  12. 12.
    Rodriguez L, Illescas LR, Ramirez R, Bustamante B, Diaz A, Hidalgo J (2014) Nosocomial bloodstream infections due to Candida spp. at a tertiary care center in Lima, Peru: Species distribution and clinical features. IDWeek, Philadelphia, PAGoogle Scholar
  13. 13.
    Montravers P (2011) A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 17(7):1061–1067CrossRefPubMedGoogle Scholar
  14. 14.
    Martínez D, Heudebert G, Seas C, Henostroza G, Rodriguez M et al (2010) Clinical prediction rule for stratifying risk of pulmonary multidrug-resistant tuberculosis. PLoS ONE 5(8):e12082CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Denning DW, Pleuvry A, Cole DC (2011) Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull WHO 89:864–872PubMedPubMedCentralGoogle Scholar
  16. 16.
    Smith N, Denning DW (2011) Underlying pulmonary disease frequency in patients with chronic pulmonary aspergillosis. Eur Respir J 37:865–872CrossRefPubMedGoogle Scholar
  17. 17.
    Perkhofer S (2010) The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents 36(6):531–536CrossRefPubMedGoogle Scholar
  18. 18.
    Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, Coignard B, Dromer F, Bretagne S, French Mycosis Study Group (2011) Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect 17:1882–1889CrossRefPubMedGoogle Scholar
  19. 19.
    Jaganath D, Miranda JJ, Gilman RH, Wise RA, Diette GB, Miele CH, Bernabe-Ortiz A, Checkley W, CRONICAS Cohort Study Group (2015) Prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru. Respir Res 16:40CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Guinea J, Torres-Narbona M, Gijon P, Munoz P, Pozo F, Pelaez T et al (2010) Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 16:870–877CrossRefPubMedGoogle Scholar
  21. 21.
    Yan X, Li M, Jiang M, Zou L, Luo F, Jiang Y (2009) Clinical characteristics of 45 patients with invasive pulmonary Aspergillosis: retrospective analysis of 1711 lung cancer cases. Cancer 115:5018–5025CrossRefPubMedGoogle Scholar
  22. 22.
    Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis 50:1091–1100CrossRefPubMedGoogle Scholar
  23. 23.
    EsSalud (2014) Estadística de producción asistencial de trasplante de órganos. Datos definitivos al mes de diciembre del 2014. EsSalud (Organ Transplant Statistic. Final data at the end of December 2014). In: http://www.essalud.gob.pe/estadistica-institucional. Accessed 30 January 2017
  24. 24.
    To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet LP (2012) Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 12:204CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Denning DW, Pleuvry A, Cole DC (2013) Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 51(4):361–370CrossRefPubMedGoogle Scholar
  26. 26.
    Agarwal R, Aggarwal AN, Gupta D, Jindal SK (2009) Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and metaanalysis. Int J Tuberc Lung Dis 13:936–944PubMedGoogle Scholar
  27. 27.
    Pappas PG, Tellez I, Deep AE, Nolasco D, Holgado W, Bustamante B (2000) Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Infect Dis 30:65–70CrossRefPubMedGoogle Scholar
  28. 28.
    Oyarce JA, Garcia C, Alave J, Bustamante B (2016) Caracterización epidemiológica, clínica y de laboratorio de esporotricosis en pacientes de un hospital de tercer nivel en Lima-Peru, entre los años 1991 y 2014. Rev Chil Infectol 33(3):315–321CrossRefGoogle Scholar
  29. 29.
    Eza D, Cerrillo G, Moore DA, Castro C, Ticona E, Morales D, Cabanillas J, Barrantes F, Alfaro A, Benavides A, Rafael A, Valladares G, Arevalo F, Evans CA, Gilman RH (2006) Postmortem findings and opportunistic infections in HIV-positive patients from a public hospital in Peru. Pathol Res Pract 202(11):767–775CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Linares-Barandiaran L, Paz J, Bustamante B (2012) Cryptococcal antigenemia in Peruvian HIV-infected patients with a CD4 cell count <100 cell/mm3. In Proceedings of the 18th Congress of the International Society for Human and Animal Mycology 2012 (ISHAM2012), Berlin, GermanyGoogle Scholar
  31. 31.
    Frola C, Guelfand L, Socias E, Sued O, Perez H, Canh P (2015) Prevalencia del antígeno de Cryptococcus y valoración de su detección como método de tamizaje en pacientes con infección avanzada por VIH. In Proceedings of the XVII Congreso de la Asociación Panamericana de Infectologia, Quito, EcuadorGoogle Scholar
  32. 32.
    Escandón P, Lizarazo J, Agudelo CI, Chiller T, Castañeda E (2013) Evaluation of a rapid lateral flow immunoassay for the detection of cryptococcal antigen for the early diagnosis of cryptococcosis in HIV patients in Colombia. Med Mycol 51(7):765–768CrossRefPubMedGoogle Scholar
  33. 33.
    Giacomazzi J, Baethgen L, Carneiro LC, Millington MA, Denning DW, Colombo AL, Pasqualotto AC, Association With The LIFE Program (2016) The burden of serious human fungal infections in Brazil. Mycoses 59(3):145–15CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Instituto de Medicina Tropical Alexander von HumboldtUniversidad Peruana Cayetano HerediaLimaPeru
  2. 2.The University of Manchester and The National Aspergillosis Centre, University Hospital of South Manchester in association with the LIFE program at www.LIFE-Worldwide.orgManchesterUK
  3. 3.Investigaciones Medicas en SaludLimaPeru

Personalised recommendations